SAB2500803
Anti-Plasminogen Activator/PLAU antibody produced in goat
affinity isolated antibody, buffered aqueous solution
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Anti-ATF, Anti-HGNC:9052, Anti-Plasminogen activator, Anti-UPA, Anti-Urokinase
Recommended Products
biological source
goat
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
human
technique(s)
indirect ELISA: suitable
western blot: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... PLAU(5328)
General description
Urokinase-type plasminogen activator is also known as PLAU and uPA. The human uPA is initially synthesized as 431 amino acid precursor with an N-terminal signal peptide (20 residues). The single chain molecule is processed into a disulfide-linked two-chain molecule of different molecular weights. Two forms of the A chain exist, starting at Ser21 (the long form) and Lys156 (the short form). The long and short A chains are unique to the high and low molecular weight forms, respectively. The long A chain contains an EGF (epidermal growth factor)-like domain, responsible for binding of the PLAU receptor. The B chain corresponds to the catalytic domain. The gene encoding it is localized on human chromosome 10.
Immunogen
Peptide with sequence C-HFLPWIRSHTKEEN from the C Terminus of the protein sequence according to NP_002649.1.
Biochem/physiol Actions
Urokinase-type plasminogen activator is a serine protease with extremely limited substrate specificity, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin. It is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
Spraggon G
Structure, 3(7), 681-691 (1995)
Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase epsilon/PRSS22.
Yasuda S
Blood, 105(10), 3893-3901 (2005)
Identification of a novel inhibitor of urokinase-type plasminogen activator.
Zhu M
Molecular Cancer Therapeutics, 6(4), 1348-1356 (2007)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service